Indoco Remedies , a pharmaceutical company, has confirmed that GST officials conducted an inspection at its office premises as part of ongoing investigations.

Regulatory Inspection Details

The inspection by GST authorities took place at the company's office, indicating potential scrutiny of tax-related matters. Such inspections are typically conducted as part of routine compliance checks or specific investigative procedures by tax authorities.

Company's Response and Cooperation

Indoco Remedies has stated that it is providing full assistance to the GST officials during the ongoing investigation. The company appears to be maintaining a cooperative stance with the regulatory authorities.

Ongoing Investigation Process

The pharmaceutical company is currently engaged in the investigation process, working alongside the GST officials to address any queries or requirements. The company's commitment to transparency and regulatory compliance is evident through its cooperative approach during this inspection phase.

As the investigation continues, Indoco Remedies remains focused on maintaining compliance with all applicable regulations while supporting the authorities in their review process.

Indoco Remedies Limited has completed the allotment of 55,700 equity shares under its Employee Stock Option Plan-2022, marking a significant step in its employee compensation strategy. The pharmaceutical company announced this development through a regulatory filing dated February 3, 2026.

Committee Approval and Meeting Details

The Nomination and Remuneration Committee of Indoco Remedies approved the share allotment during its meeting held on February 3, 2026. The committee meeting commenced at 09:00 a.m. and concluded at 09:30 a.m., demonstrating efficient decision-making processes.

Share Allotment Breakdown

The allotment involves two distinct categories of shares with different pricing structures:

The shares have been allotted to the Indoco Employees Welfare Trust, which will subsequently allocate or transfer these shares to eligible employees upon exercise of their stock options and Restricted Stock Units (RSUs).

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up capital structure:

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement also complies with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring complete regulatory adherence.

ESOP Structure Details

The Employee Stock Option Plan-2022 represents Indoco Remedies' commitment to employee participation in the company's growth. The allotted shares will be held by the ESOP Trust until eligible employees exercise their options, providing a structured mechanism for employee equity participation. The significant difference in exercise prices between the two categories reflects different grant terms within the comprehensive ESOP framework.